© The Author [2009]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
The Jupiter trial—new territory for statins?*
Centre for Nephrology, Royal Free Campus, University College London Medical School, London, UK
Correspondence and offprint requests to: David C. Wheeler; d.wheeler@medsch.ucl.ac.uk
Keywords: C-reactive protein; inflammation; Jupiter; LDL cholesterol; statins
| The first 10% of the full text of this article appears below. |
 |
Summary of key findings of the article |
|---|
The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) was designed to assess the benefit of statin therapy on first major cardiovascular events in apparently healthy men and women without hyperlipidaemia or overt cardiovascular disease, but with evidence of an activated inflammatory response. A total of 17 802 men and women with a low-density lipoprotein (LDL) cholesterol of <3.4 mmol/l (130 mg/dl) and a high-sensitivity C-reactive protein (CRP) level of 2.0 mg/l or greater were randomly assigned to receive either rosuvastatin 20 mg daily or matched placebo. The primary endpoint was the occurrence of
|
Review of the field |
|---|
|
What is in this for the practising nephrologist? |
|---|
|
Take home message |
|---|
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. N. Wardle C-reactive protein and statins: by Jupiter! Nephrol. Dial. Transplant., November 1, 2009; 24(11): 3552 - 3552. [Full Text] [PDF]
|
|